GuiZhou SanLi Pharmaceutical Co.,Ltd

Shanghai Stock Exchange 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd Gross Profit Margin for the year ending December 31, 2023: 73.31%

GuiZhou SanLi Pharmaceutical Co.,Ltd Gross Profit Margin is 73.31% for the year ending December 31, 2023, a 2.20% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

GuiZhou SanLi Pharmaceutical Co.,Ltd Gross Profit Margin for the year ending December 31, 2022 was 71.74%, a 1.76% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Gross Profit Margin for the year ending December 31, 2021 was 70.50%, a 5.47% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Gross Profit Margin for the year ending December 31, 2020 was 66.84%, a 0.97% change year over year.
GuiZhou SanLi Pharmaceutical Co.,Ltd Gross Profit Margin for the year ending December 31, 2019 was 66.20%, a 1.18% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

Shanghai Stock Exchange: 603439.SS

GuiZhou SanLi Pharmaceutical Co.,Ltd

CEO	Mr. Hai Zhang
IPO Date	April 28, 2020
Location	China
Headquarters	Xiayun Industrial Park
Employees	2,282
Sector	Health Care
Industries Pharmaceuticals

Description

GuiZhou SanLi Pharmaceutical Co.,LTD. engages in the research and development, production, and marketing of pharmaceutical products. It offers pediatric medication, respiratory system medication, cardiovascular and cerebrovascular drugs, digestive medicine, trauma injury medication, rehabilitation medicine, and ophthalmic medicine. The company was founded in 1995 and is based in Guiyang, China.

Key trends

Past 5 years